It’s tempting to just buy into big names, and trust the herd wisdom to bring market returns. And that can work – there’s …
Wall Street is experiencing some major déjà vu. The tensions between the U.
Over the weekend, Viking Therapeutics (VKTX) presented additional encouraging results from a Phase II study of VK5211 in patients recovering from hip fracture …
Viking Therapeutics (VKTX) has currently five drugs in its development pipeline. Those drugs are targeting a variety of diseases including diabetes, metabolic diseases, …
Viking Therapeutics (VKTX) shares skyrocketed over 280% year-to-date thanks to positive mid-stage results for the drug maker’s experimental nonalcoholic steatohepatitis (NASH) candidate VK2809. …
Maxim’s top analyst Jason McCarthy is out today with a bullish note on shares of Viking Therapeutics (VKTX), after the drug maker announced positive new findings …
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Viking Therapeutics …
It’s a very rewarding trading day for investors in Viking Therapeutics (VKTX) with shares up nearly 80%, making the stock Wall Street’s bull …
Following encouraging NASH data from VKTX’s biotech peer Madrigal, H.C.
Maxim’s Jason McCarthy now spotlights 67% in return potential for VKTX shares.